Zolunicant
Product Specifications
UNSPSC Description
Zolunicant (MM-110) is a potent inhibitor against nicotinic α3β4 receptors with an IC50 of 0.90 μM to combat addiction. Zolunicant can decrease the self-administration of several addictive agents including morphine, methamphetamine, nicotine, and ethanol in rat model. Zolunicant can be studied as a potential research for multiple forms of agent abuse[1]. Zolunicant also reveals a potent leishmanicide effect against Leishmania amazonensis[2].
Target Antigen
nAChR; Parasite
Type
Reference compound
Related Pathways
Anti-infection;Membrane Transporter/Ion Channel;Neuronal Signaling
Applications
COVID-19-immunoregulation
Field of Research
Infection; Neurological Disease
Assay Protocol
https://www.medchemexpress.com/zolunicant.html
Solubility
10 mM in DMSO
Smiles
COC([C@]12[C@@]3([H])[N@@](CCC4=C2NC5=CC=CC=C54)C[C@@](C[C@@H]3CCOC)([H])C1)=O
Molecular Weight
368.47
References & Citations
[1]Pace CJ, et al. Novel iboga alkaloid congeners block nicotinic receptors and reduce drug self-administration. European journal of pharmacology. 2004;492(2-3):159-67.|[2]Delorenzi JC, et al. In vitro activities of iboga alkaloid congeners coronaridine and 18-methoxycoronaridine against Leishmania amazonensis. Antimicrob Agents Chemother. 2002;46(7):2111-5.|[3]Glick SD, et al. 18-Methoxycoronaridine acts in the medial habenula and/or interpeduncular nucleus to decrease morphine self-administration in rats. European journal of pharmacology. 2006;537(1-3):94-8.
Shipping Conditions
Blue Ice
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-147428/Zolunicant-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-147428/Zolunicant-SDS-MedChemExpress.pdf
Clinical Information
No Development Reported
CAS Number
188125-42-0
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
